Drug Profile
Docetaxel - Accord
Alternative Names: AXTERE; TAXANIT; TAXOCCORDLatest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator Accord Healthcare
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer
- Registered Colorectal cancer; Ovarian cancer
Most Recent Events
- 08 Aug 2017 Registered for Colorectal cancer in Mexico (IV) (Accord Healthcare website, August 2017) before August 2017
- 15 Jul 2015 Registered for Breast cancer (Combination therapy, Adjunctive treatment, Metastatic disease) in Mexico (IV)
- 15 Jul 2015 Registered for Head and neck cancer (Combination therapy, Inoperable/Unresectable) in Mexico (IV)